[go: up one dir, main page]

SG10201805087VA - Artificial match-type mirna for controlling gene expression and use therefor - Google Patents

Artificial match-type mirna for controlling gene expression and use therefor

Info

Publication number
SG10201805087VA
SG10201805087VA SG10201805087VA SG10201805087VA SG10201805087VA SG 10201805087V A SG10201805087V A SG 10201805087VA SG 10201805087V A SG10201805087V A SG 10201805087VA SG 10201805087V A SG10201805087V A SG 10201805087VA SG 10201805087V A SG10201805087V A SG 10201805087VA
Authority
SG
Singapore
Prior art keywords
region
mirna
artificial match
type mirna
gene expression
Prior art date
Application number
SG10201805087VA
Inventor
Masahiko Kuroda
Shinichiro Ohno
Eriko Aoki
Yasuhiko Yoshida
Shiori Kato
Tadaaki Ohgi
Original Assignee
Bonac Corp
Univ Tokyo Medical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bonac Corp, Univ Tokyo Medical filed Critical Bonac Corp
Publication of SG10201805087VA publication Critical patent/SG10201805087VA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

ARTIFICIAL MATCH-TYPE miRNA FOR CONTROLLING GENE EXPRESSION AND USE THEREFOR The present invention provides a new artificial match- type miRNA utilizing miRNA. 5 A single strand nucleic acid containing X region and Y region, wherein the 3’ -terminal of the X region and the 5’ - terminal of the Y region are linked via a linker region of a non-nucleotide structure, the X region contains a guide strand sequence of a mature miRNA, and the Y region contains a 10 sequence completely complementary to the X region is an artificial match-type miRNA. The artificial match-type miRNA can suppress expression of the target gene. (No drawing to be published) 15
SG10201805087VA 2013-12-27 2014-12-27 Artificial match-type mirna for controlling gene expression and use therefor SG10201805087VA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2013273033 2013-12-27

Publications (1)

Publication Number Publication Date
SG10201805087VA true SG10201805087VA (en) 2018-07-30

Family

ID=53479025

Family Applications (3)

Application Number Title Priority Date Filing Date
SG10201805087VA SG10201805087VA (en) 2013-12-27 2014-12-27 Artificial match-type mirna for controlling gene expression and use therefor
SG11201605247XA SG11201605247XA (en) 2013-12-27 2014-12-27 Artificial match-type mirna for controlling gene expression and use therefor
SG10201913570XA SG10201913570XA (en) 2013-12-27 2014-12-27 Artificial match-type mirna for controlling gene expression and use therefor

Family Applications After (2)

Application Number Title Priority Date Filing Date
SG11201605247XA SG11201605247XA (en) 2013-12-27 2014-12-27 Artificial match-type mirna for controlling gene expression and use therefor
SG10201913570XA SG10201913570XA (en) 2013-12-27 2014-12-27 Artificial match-type mirna for controlling gene expression and use therefor

Country Status (13)

Country Link
US (1) US10934542B2 (en)
EP (1) EP3088525A4 (en)
JP (2) JP6425142B2 (en)
KR (1) KR102357337B1 (en)
CN (2) CN112646812A (en)
AU (1) AU2014370829B2 (en)
BR (1) BR112016014986A2 (en)
CA (1) CA2935022A1 (en)
IL (2) IL246395B (en)
MX (1) MX387332B (en)
RU (1) RU2697094C2 (en)
SG (3) SG10201805087VA (en)
WO (1) WO2015099187A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109810977A (en) 2012-05-26 2019-05-28 株式会社博纳克 Gene expression regulation single stranded nucleic acid molecule with delivery functions
CN105899663B (en) 2013-12-26 2019-07-26 学校法人东京医科大学 Manual simulation miRNA and application thereof for gene expression control
SG10201805087VA (en) 2013-12-27 2018-07-30 Bonac Corp Artificial match-type mirna for controlling gene expression and use therefor
AU2015368293B2 (en) 2014-12-27 2021-07-22 Bonac Corporation Naturally occuring miRNA for controlling gene expression, and use of same
HK1244031A1 (en) 2015-03-27 2018-07-27 Bonac Corporation Single-chain nucleic acid molecule having delivery function and gene expression control ability
WO2016167366A1 (en) * 2015-04-17 2016-10-20 国立大学法人 東京大学 Therapeutic agent for eye disease
ES2988534T3 (en) * 2015-10-30 2024-11-20 Toray Industries Composition stably containing a single-chain nucleic acid molecule that suppresses the expression of the TGF-ß1 gene
US11530409B2 (en) 2016-01-26 2022-12-20 Nissan Chemical Corporation Single-stranded oligonucleotide
EP3409776A4 (en) * 2016-01-30 2019-12-25 Bonac Corporation ARN UNIQUE ARTIFICIAL GUIDE AND ITS USE
US11572558B2 (en) 2017-02-06 2023-02-07 Nissan Chemical Corporation Single-stranded oligonucleotide
WO2018155487A1 (en) * 2017-02-21 2018-08-30 株式会社ボナック Nucleic acid-containing powdery preparation for dpi, and use thereof
TWI830718B (en) * 2018-02-09 2024-02-01 日商住友化學股份有限公司 Method of producing nucleic acid molecule
CA3094303A1 (en) 2018-03-20 2019-09-26 Tokyo Institute Of Technology Antisense oligonucleotide reduced in toxicity

Family Cites Families (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE873543C (en) 1942-10-28 1953-04-16 Basf Ag Process for the production of dicarbamic acid esters containing hydroxyl or sulfhydryl groups
US3687808A (en) 1969-08-14 1972-08-29 Univ Leland Stanford Junior Synthetic polynucleotides
US4550163A (en) 1979-02-05 1985-10-29 Abbott Laboratories Ligand analog-irreversible enzyme inhibitor conjugates
US20030232355A1 (en) 1992-05-22 2003-12-18 Isis Pharmaceuticals, Inc. Double-stranded peptide nucleic acids
US5631148A (en) 1994-04-22 1997-05-20 Chiron Corporation Ribozymes with product ejection by strand displacement
GB9621367D0 (en) 1996-10-14 1996-12-04 Isis Innovation Chiral peptide nucleic acids
US6197557B1 (en) 1997-03-05 2001-03-06 The Regents Of The University Of Michigan Compositions and methods for analysis of nucleic acids
EP1013770A1 (en) 1998-12-23 2000-06-28 Université Louis Pasteur de Strasbourg Non-viral transfection vector
FR2790757B1 (en) 1999-03-09 2003-08-01 Bioalliance Pharma OLIGONUCLEOTIDES CONTAINING AN ANTI-SENSE SEQUENCE STABILIZED BY A SECONDARY STRUCTURE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME.
US6852334B1 (en) 1999-04-20 2005-02-08 The University Of British Columbia Cationic peg-lipids and methods of use
WO2005019453A2 (en) 2001-05-18 2005-03-03 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA)
US7833992B2 (en) 2001-05-18 2010-11-16 Merck Sharpe & Dohme Conjugates and compositions for cellular delivery
US6962906B2 (en) 2000-03-14 2005-11-08 Active Motif Oligonucleotide analogues, methods of synthesis and methods of use
CA2439750A1 (en) 2001-03-09 2002-09-19 Boston Probes, Inc. Methods, kits and compositions pertaining to combination oligomers and libraries for their preparation
US6905827B2 (en) 2001-06-08 2005-06-14 Expression Diagnostics, Inc. Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases
WO2003037909A1 (en) 2001-10-29 2003-05-08 Mcgill University Acyclic linker-containing oligonucleotides and uses thereof
WO2003072745A2 (en) 2002-02-22 2003-09-04 Eshleman James R Antigene locks and therapeutic uses thereof
CA2479530A1 (en) 2002-03-20 2003-10-02 Massachusetts Institute Of Technology Hiv therapeutic
SI2258847T1 (en) 2002-08-05 2017-08-31 Silence Therapeutics Gmbh Futher novel forms of interfering RNA molecules
WO2004015075A2 (en) * 2002-08-08 2004-02-19 Dharmacon, Inc. Short interfering rnas having a hairpin structure containing a non-nucleotide loop
US6936651B2 (en) 2002-12-17 2005-08-30 E. I. Du Pont De Nemours And Company Compatibility improvement in crystalline thermoplastics with mineral fillers
CA2488224A1 (en) 2003-04-03 2004-10-21 Alnylam Pharmaceuticals, Inc. Irna conjugates
JP2007516695A (en) 2003-06-12 2007-06-28 アプレラ コーポレイション Combination nucleobase oligomers comprising universal base analogs and methods for making and using the same
WO2005047505A2 (en) 2003-08-07 2005-05-26 Whitehead Institute For Biomedical Research Methods and products for expression of micro rnas
WO2005030960A1 (en) 2003-09-30 2005-04-07 Anges Mg, Inc. Staple type oligonucleotide and drug comprising the same
EP1680439A2 (en) 2003-10-14 2006-07-19 Kernel Biopharma Inc. Dual phase-pna conjugates for the delivery of pna through the blood brain barrier
WO2005037317A2 (en) 2003-10-17 2005-04-28 Cornell Research Foundation, Inc. Mast cell-derived renin
AU2005327517B2 (en) 2004-06-30 2011-05-26 Alnylam Pharmaceuticals, Inc. Oligonucleotides comprising a non-phosphate backbone linkage
HRP20171010T8 (en) 2004-08-23 2017-11-03 Sylentis S.A.U. Treatment of eye disorders characterized by an elevated intraocular pressure by sirnas
EP1783137A4 (en) 2004-08-26 2014-10-22 Nippon Shinyaku Co Ltd Galactose derivative, drug carrier and medicinal composition
RU2410430C2 (en) * 2004-08-31 2011-01-27 Силентис С.А.У. Methods and compositions for inhibiting expression of p2x7 receptor
US8975471B2 (en) 2004-10-12 2015-03-10 The Rockefeller University MicroRNAs
EP2281888B1 (en) 2004-11-12 2015-01-07 Asuragen, Inc. Methods and compositions involving miRNA and miRNA inhibitor molecules
US20090005332A1 (en) 2004-12-30 2009-01-01 Hauser Todd M Compositions and Methods for Modulating Gene Expression Using Self-Protected Oligonucleotides
KR20080106437A (en) 2006-03-01 2008-12-05 니뽄 신야쿠 가부시키가이샤 Galactose Derivatives, Drug Carriers and Pharmaceutical Compositions
US8143230B2 (en) 2006-05-05 2012-03-27 Isis Pharmaceuticals, Inc. Compounds and methods for modulating expression of PCSK9
EP2584047B1 (en) * 2006-05-11 2014-11-19 Alnylam Pharmaceuticals Inc. Compositions and methods for inhibiting expression of the PCSK9 gene
EP2029597A4 (en) 2006-05-31 2011-11-23 Univ California ANALOGUES OF THE PURINE
EP1890152A1 (en) 2006-08-14 2008-02-20 Charite Universitätsmedizin-Berlin Determination of renin/prorenin receptor activity
JP2008220366A (en) 2007-02-16 2008-09-25 National Institute Of Advanced Industrial & Technology Modified PNA / RNA complex
JP5145557B2 (en) 2007-03-01 2013-02-20 財団法人ヒューマンサイエンス振興財団 Tumor growth inhibitor containing microRNA as active ingredient, and pharmaceutical composition for cancer treatment
PT2129680E (en) 2007-03-21 2015-08-28 Brookhaven Science Ass Llc Combined hairpin-antisense compositions and methods for modulating expression
CN101121934B (en) * 2007-04-11 2011-12-07 哈尔滨医科大学 Multiple target points miRNA antisense nucleic acid technique
US8399248B2 (en) 2007-05-03 2013-03-19 Merck Sharp & Dohme Corp. Methods of using MIR34 as a biomarker for TP53 functional status
JP5296328B2 (en) 2007-05-09 2013-09-25 独立行政法人理化学研究所 Single-stranded circular RNA and method for producing the same
US20090123501A1 (en) 2007-05-17 2009-05-14 Baylor College Of Medicine Inhibition of the sh2-domain containing protein tyr-phosphatase, shp-1, to enhance vaccines
WO2008147837A1 (en) 2007-05-23 2008-12-04 Dharmacon, Inc. Micro-rna scaffolds, non-naturally occurring micro-rnas, and methods for optimizing non-naturally occurring micro-rnas
WO2008150897A2 (en) 2007-05-31 2008-12-11 University Of Iowa Research Foundation Reduction of off-target rna interference toxicity
EP2171089B1 (en) 2007-06-25 2014-01-22 Universität Duisburg-Essen Screening-method for polymorphic markers in htra1 gene in neurodegenerative disorders
EP2193140B1 (en) * 2007-08-27 2016-11-02 1Globe Health Institute LLC Compositions of asymmetric interfering rna and uses thereof
WO2009048932A2 (en) 2007-10-09 2009-04-16 Children's Medical Center Corporation Methods to regulate mirna processing by targeting lin-28
US9540649B2 (en) 2007-10-12 2017-01-10 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Method for opening tight junctions
TW200927177A (en) 2007-10-24 2009-07-01 Nat Inst Of Advanced Ind Scien Lipid-modified double-stranded RNA having potent RNA interference effect
AR069328A1 (en) 2007-11-15 2010-01-13 Alcon Mfg Ltd RELEASE OF SHORT OR SIRNA INTERFERENT RNA, INTERMEDIATED BY LOW DENSITY LIPOPROTEIN RECEPTOR
JP2011504730A (en) 2007-11-29 2011-02-17 蘇州瑞博生物技術有限公司 Complex molecule interfering with target gene expression and synthesis method thereof
CA2930393C (en) 2007-12-04 2022-11-29 Alnylam Pharmaceuticals, Inc. Carbohydrate conjugates as delivery agents for oligonucleotides
US20110159586A1 (en) 2007-12-07 2011-06-30 Halo-Bio Rnai Therapeutics, Inc. Compositions and methods for modulating gene expression using asymmetrically-active precursor polynucleotides
JP5540312B2 (en) 2008-02-15 2014-07-02 独立行政法人理化学研究所 Circular single-stranded nucleic acid complex and method for producing the same
CA2719963A1 (en) 2008-03-31 2009-10-08 National Institute Of Advanced Industrial Science And Technology Double-stranded lipid-modified rna having high rna interference effect
US20110172295A1 (en) 2008-04-11 2011-07-14 The University Of North Carolina At Chapel Hill METHODS AND COMPOSITIONS FOR THE REGULATION OF microRNA PROCESSING
WO2009143619A1 (en) 2008-05-27 2009-12-03 Chum Methods of treating or preventing obesity and obesity-related hypertension
WO2010056737A2 (en) 2008-11-11 2010-05-20 Mirna Therapeutics, Inc. Methods and compositions involving mirnas in cancer stem cells
JP5794559B2 (en) 2008-11-19 2015-10-14 国立大学法人岐阜大学 Drugs for regulating differentiation of mesenchymal cells and use thereof
JP2012521766A (en) 2009-03-27 2012-09-20 メルク・シャープ・エンド・ドーム・コーポレイション RNA interference-mediated inhibition of high affinity IgE receptor α chain (FCεR1α) gene expression using small interfering nucleic acids (siNA)
JP5875976B2 (en) 2009-06-01 2016-03-02 ヘイロー−バイオ アールエヌエーアイ セラピューティクス， インコーポレイテッド Polynucleotides, compositions and methods for their use for multivalent RNA interference
US8871730B2 (en) * 2009-07-13 2014-10-28 Somagenics Inc. Chemical modification of short small hairpin RNAs for inhibition of gene expression
US20120258104A1 (en) 2009-07-22 2012-10-11 Cenix Bioscience Gmbh Delivery System and Conjugates For Compound Delivery Via Naturally Occurring Intracellular Transport Routes
WO2011028550A1 (en) 2009-08-24 2011-03-10 Merck Sharp & Dohme Corp. Segmented micro rna mimetics
US20110052666A1 (en) 2009-09-03 2011-03-03 Medtronic, Inc. Compositions, Methods, and Systems for SIRNA Delivery
US8871509B2 (en) 2009-11-06 2014-10-28 Chung-Ang University-Academy Corporation Foundation Nanoparticle-based gene delivery systems
WO2011075656A1 (en) 2009-12-18 2011-06-23 The University Of British Columbia Methods and compositions for delivery of nucleic acids
CA3009891C (en) 2009-12-23 2020-09-15 Novartis Ag Lipids, lipid compositions, and methods of using them
AU2010334799A1 (en) 2009-12-23 2012-07-12 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Influenza targets
EP3560503B1 (en) 2010-03-24 2021-11-17 Phio Pharmaceuticals Corp. Rna interference in dermal and fibrotic indications
CN101845071B (en) 2010-03-25 2012-02-01 北京欧凯纳斯科技有限公司 Nucleoside derivative of 2' or 3' coupling amino acid, preparation method and application thereof
JP5555940B2 (en) 2010-04-14 2014-07-23 国立大学法人佐賀大学 Method for detecting proliferative diabetic retinopathy and screening method for prophylactic / therapeutic agent
EP2562257A4 (en) 2010-04-19 2014-10-01 Riken METHOD FOR STABILIZING FUNCTIONAL NUCLEIC ACIDS
CA2795815C (en) 2010-04-23 2018-06-26 Cold Spring Harbor Laboratory Novel structurally designed shrnas
US8785121B2 (en) 2010-07-08 2014-07-22 Bonac Corporation Single-stranded nucleic acid molecule for controlling gene expression
PT2933333T (en) 2010-07-08 2018-04-24 Bonac Corp Single-strand nucleic acid molecule for controlling gene expression
US8618073B2 (en) * 2010-07-22 2013-12-31 The University Of North Carolina At Chapel Hill Use of miR-29 for cell protection
WO2012017919A1 (en) * 2010-08-03 2012-02-09 株式会社ボナック Single-stranded nucleic acid molecule having nitrogen-containing alicyclic skeleton
US8691782B2 (en) * 2010-08-03 2014-04-08 Bonac Corporation Single-stranded nucleic acid molecule having nitrogen-containing alicyclic skeleton
KR20130100278A (en) 2010-08-31 2013-09-10 머크 샤프 앤드 돔 코포레이션 Novel single chemical entities and methods for delivery of oligonucleotides
EP2647713B1 (en) * 2010-12-02 2018-02-21 Daiichi Sankyo Company, Limited Modified single-strand polynucleotide
CN102559666B (en) * 2010-12-18 2013-12-25 中国科学院上海生命科学研究院 Plant virus inhibitory artificial miRNA (microRNA) and construction and application thereof
WO2012106591A1 (en) * 2011-02-03 2012-08-09 Mirna Therapeutics, Inc. Synthetic mimics of mir-34
CN102784398B (en) * 2011-05-16 2014-06-18 南京大学 Composition comprising endostatin adopted as delivery system and chemically-synthesized RNA interference molecule, and application thereof
JP6011945B2 (en) 2011-05-20 2016-10-25 公一 中城 Composition comprising microRNA or expression system thereof
EP2527440A1 (en) 2011-05-27 2012-11-28 Institut Curie Cancer treatment by combining DNA molecules mimicking double strand breaks with hyperthermia
JP2013055913A (en) 2011-09-09 2013-03-28 Bonac Corp Single-stranded rna molecule for gene expression control
WO2013077446A1 (en) 2011-11-26 2013-05-30 株式会社ボナック Single-stranded nucleic acid molecule for regulating expression of gene
US9528111B2 (en) 2012-01-07 2016-12-27 Bonac Corporation Single-stranded nucleic acid molecule having amino acid backbone
JP2013153736A (en) 2012-01-07 2013-08-15 Bonac Corp Single strand nucleic acid molecule having peptide skeleton
ES2765819T3 (en) * 2012-03-04 2020-06-11 Bonac Corp Micro-RNA inhibitor
AR090905A1 (en) 2012-05-02 2014-12-17 Merck Sharp & Dohme CONJUGATES CONTAINING TETRAGALNAC AND PEPTIDES AND PROCEDURES FOR THE ADMINISTRATION OF OLIGONUCLEOTIDES, PHARMACEUTICAL COMPOSITION
CN109810977A (en) 2012-05-26 2019-05-28 株式会社博纳克 Gene expression regulation single stranded nucleic acid molecule with delivery functions
EP2975938A4 (en) 2013-03-15 2017-02-15 Ohio State Innovation Foundation Inhibitors of prmt5 and methods of their use
AU2014268529C1 (en) 2013-05-22 2020-10-01 Alnylam Pharmaceuticals, Inc. TMPRSS6 iRNA compositions and methods of use thereof
WO2015093495A1 (en) 2013-12-16 2015-06-25 株式会社ボナック Single-stranded nucleic acid molecule for controlling expression of tgf-β1 gene
CN105899663B (en) 2013-12-26 2019-07-26 学校法人东京医科大学 Manual simulation miRNA and application thereof for gene expression control
JP6492014B2 (en) * 2013-12-27 2019-03-27 株式会社ボナック Artificial match-type miRNA for gene expression control and use thereof
SG10201805087VA (en) 2013-12-27 2018-07-30 Bonac Corp Artificial match-type mirna for controlling gene expression and use therefor
US10119140B2 (en) 2014-04-18 2018-11-06 Board Of Regents Of The Nevada System Of Higher Education On Behalf Of The University Of Nevada, Reno Methods for enhancing or decreasing the levels of MIR124 and MIR29 in subjects with muscular dystrophy
AU2015368293B2 (en) 2014-12-27 2021-07-22 Bonac Corporation Naturally occuring miRNA for controlling gene expression, and use of same
HK1244031A1 (en) 2015-03-27 2018-07-27 Bonac Corporation Single-chain nucleic acid molecule having delivery function and gene expression control ability
HK1259060A1 (en) 2015-12-29 2019-11-22 国立大学法人北海道大学 Single-stranded nucleic acid molecule inhibiting expression of prorenin gene or prorenin receptor gene, and use thereof

Also Published As

Publication number Publication date
US20160319282A1 (en) 2016-11-03
JP2018145199A (en) 2018-09-20
JP6425142B2 (en) 2018-11-21
CN106068324B (en) 2020-12-29
JP6653889B2 (en) 2020-02-26
IL246395B (en) 2020-01-30
IL246395A0 (en) 2016-08-31
KR102357337B1 (en) 2022-01-28
AU2014370829A1 (en) 2016-08-11
RU2016130611A3 (en) 2018-08-27
EP3088525A4 (en) 2017-08-09
SG11201605247XA (en) 2016-08-30
BR112016014986A2 (en) 2018-01-23
CA2935022A1 (en) 2015-07-02
MX387332B (en) 2025-03-18
CN106068324A (en) 2016-11-02
US10934542B2 (en) 2021-03-02
MX2016008518A (en) 2017-01-26
JPWO2015099187A1 (en) 2017-03-23
IL271715A (en) 2020-02-27
CN112646812A (en) 2021-04-13
WO2015099187A1 (en) 2015-07-02
IL271715B (en) 2022-03-01
EP3088525A1 (en) 2016-11-02
SG10201913570XA (en) 2020-03-30
AU2014370829B2 (en) 2021-03-11
KR20160121510A (en) 2016-10-19
RU2016130611A (en) 2018-01-31
RU2697094C2 (en) 2019-08-12

Similar Documents

Publication Publication Date Title
SG10201805087VA (en) Artificial match-type mirna for controlling gene expression and use therefor
NZ630800A (en) Methods of preparing substituted nucleotide analogs
PH12018501094A1 (en) Process for the preparation of an apoptosis-inducing agent
MA39941A (en) METHODS AND MODIFICATIONS THAT PRODUCE ssRNAi COMPOUNDS WITH ENHANCED ACTIVITY, POTENCY AND DURATION OF EFFECT
SG10201900948PA (en) Modified nucleotide linkers
MX356625B (en) Oligonucleotides for making a change in the sequence of a target rna molecule present in a living cell.
CL2016003277A1 (en) Methods for preparing substituted nucleotide analogs
UA115652C2 (en) COMPOUND CONTAINING MODIFIED OLIGONUCLEOTIDE COMPLEMENTARY MIR-21
MX368142B (en) Novel cloning, expression & purification method for the preparation of ranibizumab.
MX2016007980A (en) Nucleic acid inducing rna interference modified for preventing off-target, and use thereof.
PH12018500151A1 (en) Compound targeting il-23a and b-cell activating factor (baff) and uses thereof
PH12016500574A1 (en) Compositions and methods for inhibiting expression of the alas1 gene
EP3054765A4 (en) Interfering with hd-zip transcription factor repression of gene expression to produce plants with enhanced traits
IN2015DN01811A (en)
LT3064574T (en) METHODS OF DIFFERENTIATION OF PLURIPOTENT STEM CELLS INDICATED FROM MESCHENCHEMIC STEM CELLS TO CHONDROCYTES
IN2014DN03464A (en)
MA39387A1 (en) Fluorescent reactive dyes, process for their production and their use
MX2016003248A (en) Methods of using anti-lgr5 antibodies.
MX2013011694A (en) Taxane and abeo-taxane analogs.
EA201300884A8 (en) METHOD OF OBTAINING A NEW ANTI-BACTERIAL MEDICINE ON THE BASIS OF A RECOMBINANT POLYPEPE
MX349985B (en) Process for preparing cis-alkoxy-substituted spirocyclic phenylacetylamino acid esters and cis-alkoxy-substituted spirocyclic 1-h-pyrrolidine-2,4-dione derivatives.
MX356231B (en) Multistage process for preparing alkali metal salts of specific 4-hydroxy-2-oxo-2,5-dihydrofuran-3-carboxylic esters.
UA88991U (en) Process for intensification of biogas exit
MX364769B (en) Process for producing 2-phenyl-1,3-benzoxazoles.
MX2015015346A (en) Process for the preparation of boronic acid intermediates.